Roger M. Perlmutter's most recent trade in Eikon Therapeutics Inc. was a trade of 1,268,891 Series A-1 Preferred Stock done . Disclosure was reported to the exchange on Feb. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eikon Therapeutics Inc | Roger M. Perlmutter | Director, See remarks | 06 Feb 2026 | 1,268,891 | 0 | - | - | Series A-1 Preferred Stock | ||
| Eikon Therapeutics Inc | Roger M. Perlmutter | Director, See remarks | 06 Feb 2026 | 855,512 | 0 | - | - | Series D Preferred Stock | ||
| Eikon Therapeutics Inc | Roger M. Perlmutter | Director, See remarks | 06 Feb 2026 | 284,857 | 284,857 | - | - | Common Stock | ||
| Ngm Biopharmaceuticals Inc | Roger M. Perlmutter | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 78,407 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Roger M. Perlmutter | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 46,238 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Roger M. Perlmutter | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 24,222 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Roger M. Perlmutter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 24,222 | 24,222 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Roger M. Perlmutter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 46,238 | 46,238 | - | - | Stock Option (Right to Buy) |